Avita Medical

RCEL

Market cap $157M

AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript

Recognition highlights pioneering contributions to modern burn care including development of RECELL ® Spray-On Skin™ VALENCIA, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that its founder, Professor Fiona Wood, has been awarded the Lifetime Achievement Award by the American Burn Association (ABA).

Avita Medical (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Cohealyx interim data show ~20-day reduction in time to graft vs benchmark, with strong investigator satisfaction and consistent performance across wounds.

LOS ANGELES, April 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AVITA Medical, Inc. , (“ AVITA " or the "Company") ( NASDAQ : RCEL ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

AVITA Medical highlights new Cohealyx data and real-world evidence at upcoming ABA 2026, advancing wound healing and improving patient recovery outcomes

The consensus price target hints at a 29.9% upside potential for Avita Medical (RCEL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

VALENCIA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced Cary Vance, Interim CEO, and David O'Toole, CFO, will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA.

Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AVITA Medical, Inc. (RCEL) Discusses Financial Performance, Sales Strategy, and Reimbursement Progress Transcript